Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an analysis on Brookfield stock

1 extracted signal · 1 resolved · 0 still active

The Patient Investor profile imageThe Patient Investor17 Sept 2025, 21:28 UTC
Video preview for Friends! In this video, I'm going to do an analysis on Brookfield stock
Signals
1
Eligible signals in this source
Open
0
Still being tracked
Resolved
1
Evaluable outcomes
Successful
0
Canonical correct result
Failed
1
Canonical failed result
Resolved success
0%
Open and excluded signals omitted
Source overview

AI-generated source summary

The analysis focuses on Brookfield Corporation (BN), currently trading at $67.80. The analyst believes it is undervalued and should be trading at $80 to $85 in the short term. He mentions BN has outperformed global equity markets over the last 30 years with a 19% annualized return, compared to 11% for the S&P 500. Over the last 5 years, BN has delivered a 22% annual return. The analyst also discusses the company's business model which includes asset management, insurance, and real estate. He mentions the company is aiming for an annualized DE (distributable earnings) per share growth of 17% until 2030 with a longer-term growth rate for a 25% CAGR. He explains that the company owns about $12 billion worth of direct investments and generates about 54% of net profit.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

The Patient Investor

Tracked signals
292
Historical success
32.9%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.